Companies › Bambusa Therapeutics
2 active drug programs in 6 registered trials: 6 Phase 1; Immunology, Respiratory; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BBT002 | – | Phase 1 | Chronic Obstructive Pulmonary Disease (COPD); Chronic Obstructive Pulmonary Disease; Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | Dec 2026 |
| BBT001 | – | Phase 1 | Atopic Dermatitis; Chronic Spontaneous Urticaria | Feb 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07288554 | BBT002 | Phase 1 | Chronic Obstructive Pulmonary Disease (COPD) | Respiratory | Dec 2026 |
| NCT06944925 | BBT002 | Phase 1 | Chronic Obstructive Pulmonary Disease | Respiratory | Jan 2027 |
| NCT06808477 | BBT001 | Phase 1 | Atopic Dermatitis | Immunology | Feb 2027 |
| NCT07717905 | BBT001 | Phase 1 | Chronic Spontaneous Urticaria | Immunology | Dec 2027 |
| NCT07239947 | BBT001 | Phase 1 | Atopic Dermatitis | Immunology | Dec 2027 |
| NCT07436949 | BBT002 | Phase 1 | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | Respiratory | Dec 2027 |
Press releases filed as 8-K in the last year:
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.